965 NO EXCESS MORTALITY AFTER PROSTATE BIOPSY: RESULTS FROM THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC)

2010 ◽  
Vol 9 (2) ◽  
pp. 302-303
Author(s):  
S.C. Carlsson ◽  
E. Holmberg ◽  
A.P. Auvinen ◽  
S.M. Moss ◽  
M.J. Roobol ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Excess Mortality ◽  
Randomized Study

No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer

2010 ◽  
Vol 107 (12) ◽  
pp. 1912-1917 ◽  
Author(s):  
Sigrid V. Carlsson ◽  
Erik Holmberg ◽  
Sue M. Moss ◽  
Monique J. Roobol ◽  
Fritz H. Schröder ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Excess Mortality ◽  
Randomized Study

scholarly journals The use of European Randomized study of Screening for Prostate Cancer calculator as a diagnostic tool for prostate biopsy indication

2019 ◽  
Vol 120 (05) ◽  
pp. 331-335
Author(s):  
J. Breza ◽  
F. Subin ◽  
M. Bernadic ◽  
M. Tomas ◽  
D. Pindak
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Diagnostic Tool ◽  
Randomized Study

The Incidence of Prostate Cancer in Men With Prostate Specific Antigen Greater Than 4.0 Ng/Ml:: A Randomized Study Of 6 Versus 12 Core Transperineal Prostate Biopsy

2004 ◽  
Vol 171 (1) ◽  
pp. 197-199 ◽  
Author(s):  
PAOLO EMILIOZZI ◽  
PAOLO SCARPONE ◽  
FRANCESCO DePAULA ◽  
MAURIZIO PIZZO ◽  
GIORGIO FEDERICO ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Prostate Biopsy ◽  
Randomized Study ◽  
Specific Antigen ◽  
Transperineal Prostate Biopsy

Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

2017 ◽  
Vol 120 (3) ◽  
pp. 394-400 ◽  
Author(s):  
Peter K. Chiu ◽  
Arnout R. Alberts ◽  
Lionne D. F. Venderbos ◽  
Chris H. Bangma ◽  
Monique J. Roobol
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Randomized Study ◽  
Additional Benefit ◽  
Selection For ◽  
Biopsy Complications

scholarly journals Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports

BMC Urology ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Pieter Minnee ◽  
Daphne Hessels ◽  
Jack A. Schalken ◽  
Wim Van Criekinge
Keyword(s):  
Prostate Cancer ◽  
Risk Score ◽  
Prostate Biopsy ◽  
Case Reports ◽  
Randomized Study ◽  
Risk Scores ◽  
High Grade ◽  
Molecular Biomarker ◽  
Life Years ◽  
Clinically Significant

Abstract Background Identifying men for a repeat prostate biopsy is a conundrum to urologists. Risk calculators (RCs) such as the European Randomized Study of Screening for Prostate Cancer (ERSPC) RCs have been developed to predict the outcome of prostate biopsies and have been shown to improve diagnostic accuracy compared to PSA alone. However, it was recently shown that the outcome for high-grade prostate cancer (PCa) upon biopsy tended to be underestimated in men with previous negative biopsies using ERSPC RC model 4. For these men, an individualized approach combining the clinical information with the outcome of biomarker-related urine tests may help to make a more informed decision. Case presentation Two men, aged 66 and 69 respectively when presented in the clinic, show the typical dilemma of urologist and patient for electing repeat prostate biopsy. Both men had normal DRE findings, did not have a family history of PCa, presented with serum PSA values between 3 and 10 ng/ml and the first biopsies were negative for disease. The ERSPC RC4 did not indicate a biopsy in these men. The urinary molecular biomarker-based test for HOXC6 and DLX1, combining biomarker-expression profiling with clinical risk factors, resulted in SelectMDx Risk scores for these men that were higher than the cut-off of the test. Based on this outcome, mpMRI was performed with an outcome of PI-RADS ≥4 in both men. Histopathological evaluation of TRUS-guided biopsies confirmed high-grade PCa. Conclusions The urinary molecular biomarker-based risk score played a pivotal role in the diagnosis of clinically significant PCa whereas ERSPC RC4 outcome would not have indicated further diagnostic follow-up in these two cases. The timely diagnosis was shown to be crucial for the curative treatment by radical retropubic prostatectomy and the potential life-years gained for these two vital males.

Sign in / Sign up

Export Citation Format

Share Document